Imaxio Is A Biopharmaceutical Company Based In Lyonfounded In 2000It Specializes In Vaccines And Genomicsfocusing On Integrated Research And Development Along With Commercial Activitiesthe Company Has Expertise In Vaccine Developmentimmunostimulant Technologiesand High Throughput Genomic Applications Imaxio S Vaccine Portfolio Includes Spirolepta A Vaccine For Leptospirosisand Imx313A Technology That Enhances Vaccine Effectivenessthe Company Also Develops Companion Diagnostic Tests For Oncology And Immunology And Provides Genomic Services Across Various Sectorsimaxio Combines Organic Growth Through Product Commercialization With Strategic Acquisitions To Expand Its Technology Offeringsit Collaborates With Partners To Co Develop Vaccines And Has A Spin Offosivaxwhich Focuses On Advancing Its Oligodomatechnology For Vaccine Developmentwith A Commitment To Addressing Public Health Challenges And Supporting Precision Medicineimaxio Is Positioned At The Intersection Of Vaccinology And Genomics
